Uromonitor

Uromonitor

Molecular urine testing for bladder cancer surveillance pathways.

Uromonitor® is a non-invasive molecular urine test designed to support bladder cancer surveillance and pathway triage by detecting tumour-associated DNA signals from a urine sample.

Discuss Implementation View Evidence
Non-invasive sample Uses urine testing to support surveillance decisions.
Molecular detection Designed to detect tumour-associated genetic signals.
Clinician-led use Supports decision-making within a governed pathway.
Molecular diagnostics laboratory showing urine sample tube and digital PCR equipment
Urine sample Non-invasive
dPCR analysis Molecular test
Result report Clinical signal
Decision support Pathway use

What is Uromonitor?

Uromonitor is a molecular urine test used to support bladder cancer surveillance and triage. It is designed to provide additional biological information from a urine sample, helping clinicians decide which patients may need faster cystoscopy and which patients may be suitable for continued risk-adapted follow-up.

Workflow showing urine sample collection, digital PCR analysis and clinician review
01

Urine-based testing

The pathway begins with a non-invasive urine sample, reducing reliance on immediate invasive procedures for suitable surveillance patients.

02

Molecular analysis

The sample is analysed for molecular signals associated with bladder cancer, supporting a more precise approach to pathway triage.

03

Clinical interpretation

Results should be interpreted alongside recurrence risk, cytology, symptoms, clinical history and clinician judgement.

How It Works

From urine sample to pathway decision.

Uromonitor adds molecular information into the bladder cancer surveillance pathway, supporting risk-adapted decision-making without replacing clinical review.

1

Patient selected

The clinician identifies a suitable surveillance or pathway triage use case.

2

Urine sample

A urine sample is collected through a non-invasive process.

3

dPCR testing

The sample is processed using molecular diagnostic technology.

4

Result reported

The result provides an additional signal for clinical review.

5

Decision made

The clinician decides whether to reassure, monitor or escalate to cystoscopy.

Molecular Diagnostics

Built around precision, workflow and clinical utility.

Uromonitor is strongest when used as part of a defined clinical pathway. The purpose is not simply to add another test, but to improve the timing and quality of bladder cancer surveillance decisions.

Molecular signal Supports detection of tumour-associated DNA signals from a urine sample.
Non-invasive pathway Allows suitable patients to be assessed through urine testing before invasive investigation.
Clinical triage Can support escalation where molecular or clinical concern is higher.
Surveillance support Helps services make follow-up more risk-adapted and capacity-conscious.
Decision Support

Uromonitor supports decisions. It does not remove clinical judgement.

Uromonitor should be positioned as an adjunct to cystoscopy and cytology within a governed bladder cancer pathway. It can support reassurance, escalation or continued surveillance decisions when interpreted alongside the wider clinical picture.

✓ Supports bladder cancer surveillance and pathway triage.
✓ Provides molecular information from a non-invasive urine sample.
✓ Helps prioritise cystoscopy where clinical or molecular concern is higher.
✓ Should be used inside a clinician-led, governed implementation model.
Clinician reviewing molecular diagnostic report for urology pathway decision support

Discuss Uromonitor adoption.

Speak to Progen Diagnostics about how Uromonitor could be introduced into bladder cancer surveillance pathways across NHS, private provider or laboratory settings.

Discuss Implementation